Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Artigo em Russo | MEDLINE | ID: mdl-28805757

RESUMO

AIM: To study an influence of cytoflavin therapy on the cerebral hemodynamics in patients with various stages of hypertensive disease (HD). MATERIAL AND METHODS: One hundred and forty patients with HD, I-III stages, were randomized into 2 groups: patients of group 1 received complex treatment (antihypertensive therapy and cytoflavin), patients of group 2 were treated with antihypertensive therapy. The control group consisted of 30 healthy people. The changes in cerebral hemodynamics using the algorithm of the complex ultrasound study of cerebral vascular system were assessed. RESULTS: Disturbances of hemodynamics at all structural/functional levels of cerebral vascular system were found in all HD stages. There were a decrease in the blood flow through the common carotid, inner carotid, spinal and middle cerebral arteries, reactivity of veins of Rosenthal, blood flow through veins of Rosenthal and inner jugular veins and an increase of blood flow through spinal veins. The hemodynamic study showed that in group 1 there was the increase of blood flow through common carotid, inner carotid, middle cerebral arteries in stage I and through spinal arteries in stage I-II of HD; improvement of the reactivity of veins of Rosenthal, restoration of blood flow parameters through the veins of Rosenthal and inner jugular veins to control values, the decrease in blood flow velocity through the spinal veins in all HD stages. CONCLUSION: HD is accompanied by the damage of all structural/functional levels of cerebral vascular system. The use of cytoflavin in the complex therapy of HD exerts a positive influence on the cerebral hemodynamics reducing the severity of arterial insufficiency in the initial stages of disease, improving microcirculation and venous hemodynamics in all HD stages.


Assuntos
Circulação Cerebrovascular/efeitos dos fármacos , Mononucleotídeo de Flavina/farmacologia , Hemodinâmica/efeitos dos fármacos , Hipertensão/tratamento farmacológico , Inosina Difosfato/farmacologia , Niacinamida/farmacologia , Succinatos/farmacologia , Idoso , Anti-Hipertensivos/uso terapêutico , Velocidade do Fluxo Sanguíneo/efeitos dos fármacos , Encéfalo/irrigação sanguínea , Encéfalo/diagnóstico por imagem , Combinação de Medicamentos , Quimioterapia Combinada , Feminino , Mononucleotídeo de Flavina/uso terapêutico , Humanos , Inosina Difosfato/uso terapêutico , Masculino , Microcirculação/efeitos dos fármacos , Pessoa de Meia-Idade , Niacinamida/uso terapêutico , Succinatos/uso terapêutico , Ultrassonografia
2.
Ter Arkh ; 88(5): 55-61, 2016.
Artigo em Russo | MEDLINE | ID: mdl-27239928

RESUMO

AIM: To evaluate the impact of incorporating cytoflavin in a treatment regimen for patients with different stages of hypertensive disease (HD). SUBJECTS AND METHODS: The results of treatment were analyzed in 140 patients with HD (53 with Stage I, 50 with Stage II, and 37 with Stage III). According to the treatment regimen, the patients were divided into 2 groups. A study group (n=74) received combination treatment involving antihypertensive therapy and cytoflavin intravenously dropwisely in a single dose of 200 ml of 5% glucose solution for 10 days, then 2 tablets twice daily for 60 days, with a total cycle time being 70 days. A comparison group (n=66) had antihypertensive therapy only. Thirty apparently healthy individuals (a control group) were examined to have reference values. All the patients were examined using conventional clinical and laboratory studies. The patients' complaints and neurological status were assessed using respective questionnaires over time - before and after treatment. RESULTS: The incorporation of cytoflavin in a treatment regimen was ascertained to reduce the degree of anxiety, depressive, dissomnic, and cognitive disorders, improves quality of life in patients with Stage I HD, and lowers the degree of asthenic and autonomic disorders in all disease stages. CONCLUSION: The found efficacy and safety of the drug may recommend its incorporation in combination therapy regimens for Stages I-III HD.


Assuntos
Anti-Hipertensivos/farmacologia , Ansiedade/tratamento farmacológico , Doenças do Sistema Nervoso Autônomo/tratamento farmacológico , Transtornos Cognitivos/tratamento farmacológico , Depressão/tratamento farmacológico , Mononucleotídeo de Flavina/farmacologia , Hipertensão/tratamento farmacológico , Inosina Difosfato/farmacologia , Niacinamida/farmacologia , Succinatos/farmacologia , Adulto , Idoso , Anti-Hipertensivos/administração & dosagem , Combinação de Medicamentos , Quimioterapia Combinada , Feminino , Mononucleotídeo de Flavina/administração & dosagem , Humanos , Inosina Difosfato/administração & dosagem , Masculino , Pessoa de Meia-Idade , Niacinamida/administração & dosagem , Índice de Gravidade de Doença , Succinatos/administração & dosagem , Resultado do Tratamento
3.
Artigo em Russo | MEDLINE | ID: mdl-26356615

RESUMO

AIM: To compare clinical and morphological results of treatment of ischemic stroke in three groups of patients which differed by the forms and duration of an antioxidant therapy. MATERIAL AND METHODS: A randomized clinical trial was performed in 8 vascular centers of the Russian Federation in 2010-2014. It included 373 patients with ischemic stroke in the carotid territory. Patients were randomized into 3 groups to receive different regimens of antioxidant therapy as an adjunct to standard therapy: control group (ascorbic acid; 132 patients); cytoflavin (20 ml per day for 10 days; 133 patients); cytoflavin (the dose was decreased to 10 ml per day from 11th to 20th day) (108 patients). Patient's condition was assessed in 1, 10 and 21 day by a complex of clinical, laboratory and instrumental methods. RESULTS AND CONCLUSION: The analysis of CT in 1th and 21th day revealed a significant 1,5-1,7- fold decrease in the cerebral ischemic lesion in both groups treated with cytoflavin with no significant morphologic changes in the ascorbic acid group. The percentage of patients with ischemic lesion, increased during days 1-21, was 2-fold higher in the ascorbic acid group compared to cytoflavin groups. Morphologic changes were correlated with clinical variables and outcome. In patients with ≥14 points on NIH scale on admission, prolonged 20 day cytoflavin therapy was associated with a more prominent improvement of neurologic, functional and cognitive status compared to 10-day cytoflavin infusion. No differences in clinical variables were observed in patients with mild symptoms (<14 points on NIH scale on admission) receiving cytoflavin for 10 and 20 days.


Assuntos
Antioxidantes/uso terapêutico , Ácido Ascórbico/uso terapêutico , Infarto Encefálico/tratamento farmacológico , Infarto Encefálico/patologia , Mononucleotídeo de Flavina/uso terapêutico , Inosina Difosfato/uso terapêutico , Niacinamida/uso terapêutico , Succinatos/uso terapêutico , Adulto , Idoso , Idoso de 80 Anos ou mais , Antioxidantes/administração & dosagem , Ácido Ascórbico/administração & dosagem , Infarto Encefálico/diagnóstico por imagem , Combinação de Medicamentos , Metabolismo Energético , Feminino , Mononucleotídeo de Flavina/administração & dosagem , Humanos , Infusões Intravenosas , Inosina Difosfato/administração & dosagem , Masculino , Pessoa de Meia-Idade , Niacinamida/administração & dosagem , Federação Russa , Succinatos/administração & dosagem , Tomografia Computadorizada por Raios X , Resultado do Tratamento
4.
Antibiot Khimioter ; 59(7-8): 30-6, 2014.
Artigo em Russo | MEDLINE | ID: mdl-25975105

RESUMO

One hundred forty patients (the average age of 46.7 ± 7.7 years) with hypertensive encephalopathy (HE) were observed. 74 patients of the main group received Cytoflavin in a dose of 2 tablets twise a day in the standard basic therapy. 66 patients of the reference group received the basic therapy alone. The arterial endothelium function was estimated and ultrasonic examination of the hemodynamics at five structurally functional levels of the cerebral vascular course was used. All the patients with HE had endothelial dysfunction, bloodstream depression in the arterial course of the brain vascular system, decreased reactivity of the intracranial veins, difficulty in venous outflow. In the course of the therapy with Cytoflavin restotation of the arterial endothelial function in the patients with HE I stage, the linear and volume speed of bloodstream in the main and intracranial cerebral arteries in the patients with HE I-II stages, restoration of the intracranial veins reactivity, the linear speed of bloodstream in intracranial veins in the patients with all three stages of HE, the linear speed of bloodstream in the main veins up to the control values in the patients with I-III stages of HE were observed. Interrelation between the values of the cerebral hemodynamics and the state of the endothelium function was shown.


Assuntos
Artérias Cerebrais/efeitos dos fármacos , Endotélio Vascular/efeitos dos fármacos , Mononucleotídeo de Flavina/farmacologia , Encefalopatia Hipertensiva/tratamento farmacológico , Inosina Difosfato/farmacologia , Fármacos Neuroprotetores/farmacologia , Niacinamida/farmacologia , Succinatos/farmacologia , Adulto , Idoso , Encéfalo/irrigação sanguínea , Encéfalo/efeitos dos fármacos , Encéfalo/patologia , Artérias Cerebrais/diagnóstico por imagem , Artérias Cerebrais/patologia , Esquema de Medicação , Combinação de Medicamentos , Endotélio Vascular/diagnóstico por imagem , Endotélio Vascular/patologia , Feminino , Hemodinâmica/efeitos dos fármacos , Humanos , Encefalopatia Hipertensiva/diagnóstico por imagem , Encefalopatia Hipertensiva/patologia , Masculino , Pessoa de Meia-Idade , Ultrassonografia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...